We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Elan Corporation, plc today announced that it has entered into
a License Agreement with Abbott Pharmaceutical PR Ltd in which Abbott has been granted US rights, in a partnership with AstraZeneca Pharmaceuticals, LP, to utilize Elan' proprietary NanoCrystal Technology to develop and commercialize a single fixed-dose combination product containing the active pharmaceutical ingredients in Abbott's TriCor145 (fenofibrate) and AstraZeneca's Crestor (rosuvastatin calcium) products.
Biophan Technologies recently received $1 million in funding from the U.S. government to further the development of the MYO-VAD cardiac support system.
Lawmakers and government regulators need to consider the cost savings that devices and diagnostics offer to the U.S. healthcare system when making decisions that could affect patients' access to new treatments, say industry leaders and at least one Senate lawmaker.
NovaDel Pharma today announced the submission of the New Drug Application (NDA) for Zensana (Ondansetron HCl) Oral Spray to the US Food and Drug Administration (FDA) by its partner Hana Biosciences.
New guidelines for the import and manufacture of medical devices in India have now come into effect, aimed at increasing world confidence in medical devices made in the region.
A four-year follow-up study published in the July issue of Journal of Spinal Disorders & Techniques, a prestigious scientific journal, supports previous results that show patients suffering from lumbar spinal stenosis have significantly greater improvement with a new, minimally invasive procedure, the X STOP Interspinous Process Decompression (IPD) System ("X STOP") and remained stable over time.